News Releases Year None20242023202220212020 Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference Aug 28, 2024 Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements Aug 08, 2024 Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 Jul 29, 2024 Tarsus to Participate in Upcoming Investor Conferences May 29, 2024 Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference May 09, 2024 Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements May 08, 2024 Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 May 01, 2024 Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon Apr 23, 2024 Tarsus to Participate at Upcoming Investor Conferences Mar 05, 2024 Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis Mar 05, 2024 Pagination Current page 1 Page 2 Next page next › Last page last » Presentations Tarsus Corporate Presentation August 12, 2024 Tarsus Second Quarter 2024 Earnings Presentation August 9, 2024 Ersa Phase 2a Study Evaluating TP-03 for the Treatment of MGD in Patients with DemodexMites Topline Data Presentation December 11, 2023 XDEMVY Approval Webcast Presentation July 25, 2023 Creating the Next Potential Blockbuster Category in Eye Care June 15, 2023 Tarsus Saturn-2 Phase 3 Trial Topline Results Presentation May 4, 2022 Revolutionizing Treatment for Demodex Blepharitis Patients Webcast Presentation February 10, 2022
Ersa Phase 2a Study Evaluating TP-03 for the Treatment of MGD in Patients with DemodexMites Topline Data Presentation December 11, 2023